Patent · US Active

Compositions and methods for inhibition of the JAK pathway

US9481654B2 · kind B2 · utility

6Cited by

7References

19Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Hui Li · Santa Clara, US
Ankush Argade · Foster City, US
Kin Tso · San Francisco, US
Sambaiah Thota · Fremont, US
David Carroll · San Francisco, US
Arvinder Sran · Fremont, US
Robin Cooper · St. Augustine, US
Rajinder Singh · Belmont, US
Somasekhar Bhamidipati · Foster City, US
Vanessa Taylor · San Francisco, US
Esteban Masuda · Menlo Park, US

Key dates

Filing date	Feb 17, 2015
Grant date	Nov 1, 2016
Priority date	—
Expiry date	Feb 17, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.